Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study

L. Minig, F. Heitz, D. Cibula, JN. Bakkum-Gamez, A. Germanova, SC. Dowdy, E. Kalogera, I. Zapardiel, K. Lindemann, P. Harter, G. Scambia, M. Petrillo, C. Zorrero, V. Zanagnolo, JMC. Rebollo, A. du Bois, C. Fotopoulou,

. 2017 ; 24 (9) : 2720-2726. [pub] 20170612

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024946
E-zdroje Online Plný text

NLK Free Medical Journals od 1994 do Před 24 měsíci
ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2009-07-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 28608122
DOI 10.1245/s10434-017-5919-y
Knihovny.cz E-zdroje

OBJECTIVE: The aim of this study was to determine oncological outcomes and incidence of lymph node (LN) metastases in women who underwent systematic pelvic and paraaortic lymphadenectomy for surgical staging of apparent stage I low-grade epithelial ovarian cancer (LGEOC). MATERIALS AND METHODS: A retrospective study was performed at nine institutions across Europe and the US, and patients who underwent surgical staging for presumed stage I LGEOC between 2000 and 2016 were included. To ensure surgical quality, a minimum number of ≥10 pelvic and ≥10 paraaortic LNs was required. Patients with preoperative radiologic or clinical evidence of extraovarian or LN disease, and those with nonepithelial histology, were excluded. RESULTS: The overall incidence of LN metastases was 4.3% in the 163 evaluated patients, and the incidence of LN involvement in serous, endometrioid, and mucinous subtypes was 10.7, 1.5, and 0%, respectively. However, Upstaging due to LN involvement alone occurred in only 2.4% of the patients. Eighty-nine (54.6%) patients received adjuvant chemotherapy due to International Federation of Gynecology and Obstetrics stage IC or higher disease. The 5-year progression-free survival (PFS) and overall survival (OS) were 93.2% (95% confidence interval [CI] 89.4-97.1%) and 94.5% (95% CI 90.9-98.0%), respectively. There was no significant difference in PFS or OS between LN-negative and LN-positive patients. However, fewer patients received adjuvant chemotherapy in the LN-negative group. Multivariate analysis did not identify any independent prognostic factor of survival. CONCLUSION: The risk of LN involvement in nonserous apparent stage I LGEOC appears low, with a rate of <1% in this retrospective analysis, raising questions about the value of lymphadenectomy in those patients. Larger-scale prospective studies are warranted to evaluate the oncologic safety of omitting systematic LN staging in apparent stage I nonserous LGEOC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024946
003      
CZ-PrNML
005      
20240731111638.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1245/s10434-017-5919-y $2 doi
035    __
$a (PubMed)28608122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Minig, Lucas $u Department of Gynecology, Instituto Valenciano de Oncología (IVO), Valencia, Spain. miniglucas@gmail.com.
245    10
$a Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study / $c L. Minig, F. Heitz, D. Cibula, JN. Bakkum-Gamez, A. Germanova, SC. Dowdy, E. Kalogera, I. Zapardiel, K. Lindemann, P. Harter, G. Scambia, M. Petrillo, C. Zorrero, V. Zanagnolo, JMC. Rebollo, A. du Bois, C. Fotopoulou,
520    9_
$a OBJECTIVE: The aim of this study was to determine oncological outcomes and incidence of lymph node (LN) metastases in women who underwent systematic pelvic and paraaortic lymphadenectomy for surgical staging of apparent stage I low-grade epithelial ovarian cancer (LGEOC). MATERIALS AND METHODS: A retrospective study was performed at nine institutions across Europe and the US, and patients who underwent surgical staging for presumed stage I LGEOC between 2000 and 2016 were included. To ensure surgical quality, a minimum number of ≥10 pelvic and ≥10 paraaortic LNs was required. Patients with preoperative radiologic or clinical evidence of extraovarian or LN disease, and those with nonepithelial histology, were excluded. RESULTS: The overall incidence of LN metastases was 4.3% in the 163 evaluated patients, and the incidence of LN involvement in serous, endometrioid, and mucinous subtypes was 10.7, 1.5, and 0%, respectively. However, Upstaging due to LN involvement alone occurred in only 2.4% of the patients. Eighty-nine (54.6%) patients received adjuvant chemotherapy due to International Federation of Gynecology and Obstetrics stage IC or higher disease. The 5-year progression-free survival (PFS) and overall survival (OS) were 93.2% (95% confidence interval [CI] 89.4-97.1%) and 94.5% (95% CI 90.9-98.0%), respectively. There was no significant difference in PFS or OS between LN-negative and LN-positive patients. However, fewer patients received adjuvant chemotherapy in the LN-negative group. Multivariate analysis did not identify any independent prognostic factor of survival. CONCLUSION: The risk of LN involvement in nonserous apparent stage I LGEOC appears low, with a rate of <1% in this retrospective analysis, raising questions about the value of lymphadenectomy in those patients. Larger-scale prospective studies are warranted to evaluate the oncologic safety of omitting systematic LN staging in apparent stage I nonserous LGEOC.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aorta $7 D001011
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a lymfadenektomie $7 D008197
650    _2
$a lymfatické uzliny $x patologie $x chirurgie $7 D008198
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory glandulární a epitelové $x farmakoterapie $x sekundární $x chirurgie $7 D009375
650    _2
$a nádory vaječníků $x farmakoterapie $x patologie $x chirurgie $7 D010051
650    _2
$a pánev $7 D010388
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Heitz, Florian $u Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136, Essen, Germany.
700    1_
$a Cibula, David $u Department of Obstetrics and Gynecology, Gynecologic Oncology Centre, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Bakkum-Gamez, Jamie N $u Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Germanova, Anna $u Department of Obstetrics and Gynecology, Gynecologic Oncology Centre, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Dowdy, Sean C $u Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kalogera, Eleftheria $u Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain.
700    1_
$a Lindemann, Kristina $u Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
700    1_
$a Harter, Philipp $u Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136, Essen, Germany.
700    1_
$a Scambia, Giovanni $u Department of Women's and Children's Health, Catholic University of the Sacred Heart, Rome, Italy.
700    1_
$a Petrillo, Marco $u Department of Women's and Children's Health, Catholic University of the Sacred Heart, Rome, Italy.
700    1_
$a Zorrero, Cristina $u Department of Gynecology, Instituto Valenciano de Oncología (IVO), Valencia, Spain.
700    1_
$a Zanagnolo, Vanna $u Department of Gynecology, European Institute of Oncology, Milan, Italy.
700    1_
$a Rebollo, José Miguel Cárdenas $u Department of Applied Mathematics and Statistics, CEU San Pablo University, Madrid, Spain.
700    1_
$a Du Bois, Andreas, $d 1956- $u Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136, Essen, Germany. $7 xx0320625
700    1_
$a Fotopoulou, Christina $u Department of Gynaecology, Imperial College London, London, UK.
773    0_
$w MED00000441 $t Annals of surgical oncology $x 1534-4681 $g Roč. 24, č. 9 (2017), s. 2720-2726
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28608122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20240731111636 $b ABA008
999    __
$a ok $b bmc $g 1317077 $s 1021867
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 24 $c 9 $d 2720-2726 $e 20170612 $i 1534-4681 $m Annals of surgical oncology $n Ann Surg Oncol $x MED00000441
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace